Abstract:Wei Xiang, Zhen Guo, Yiming Zhang, Yuanzhi Xu Department of Stomatology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China Correspondence: Yuanzhi Xu; Yiming Zhang, Email ; Background: Hypertrophic scars (HS) are dermal diseases characterized by excessive fibroblast proliferation and collagen deposition following burns or trauma. While Tenascin-C (TNC)'s role in promoting visceral fibrosis has been established, its impact on skin tissue fibrosis remains unclear. This study aims to investigate the effects of TNC on HS. Methods: RNA sequence and IHC techniques were used to examine the upregulation of TNC gene in human hypertrophic scar tissue compared to normal tissues. Knockdown of TNC in Human skin fibroblasts (HFF-1) cells was achieved, and expression of Col1 and Col3 was evaluated using qPCR. Sirius red collagen staining assessed impact on total collagen content and ECM deposition. Effects on cell proliferation and migration were investigated through cck-8 and cell scratch experiments. Lentivirus infection was used to knock out TNC, and resulting samples were injected into ear wound of rabbits. Effects of TNC knockout on ear scar formation were measured using digital morphology, ultrasound, SEI, H&E, and Masson trichrome methods. Results: Cell experiments: downregulation of TNC decreased Col1 and Col3 expression, leading to reduced collagen production and extracellular matrix deposition. It did not affect HFF-1 cell proliferation and migration. Animal experiments: TNC knockdown promoted wound healing and reduced collagen deposition in rabbit ears. Conclusion: This study suggests that knocking down TNC inhibits collagen formation and extracellular matrix deposition, thereby inhibiting hypertrophic scar formation. Therefore, TNC can be considered a potential biomarker for HS formation and may offer promising treatment strategies for clinical management of hypertrophic scars. Keywords: Tenascin-C, hypertrophic scars, rabbit ear scar model, HFF-1 Hypertrophic scars (HS) are a prevalent fibroproliferative skin disease that can cause pain, itching, limited joint mobility, and deformities, significantly impacting the mental well-being of patients. 1 The characteristics of HS include excessive proliferation of skin fibroblasts, increased collagen generation, and deposition of extracellular matrix (ECM). 2 Numerous studies have investigated the underlying causes of HS, including genetics, biomechanics, metabolism, endocrinology, and immunology. 3 Type I and type III collagen are the primary components of ECM and play a crucial role in the development and progression of HS, with increased expression in HS tissues. Current treatment options for HS include surgery, radiotherapy, and combination therapy. 4,5 However, their effectiveness is still uncertain, highlighting the need for an efficient, convenient, sustainable, low-cost, and minimally side-effect treatment method that inhibits collagen production and ECM deposition. In recent years, there has been a growing interest in scar formation, particularly in relation to experimental and genomic factors. 6 It is widely acknowledged that various biochemical stimuli during wound healing, such as physical tension, the expression of transforming growth factor β genes, and abnormal proliferation of fibroblasts, play a significant role in the development of pathological scars. 7,8 In order to gain a better understanding of scar management, we have conducted an analysis of genes and their regulatory factors. The molecular mechanism behind the formation of hypertrophic scars has attracted considerable attention, as it holds potential for gene therapy of HS. 9,10 Existing evidence suggests that Tenascin-C (TNC) is expressed during embryogenesis, cancer transformation, and wound healing. 11,12 Although TNC expression is relatively low in normal adult skin, it significantly increases during the process of wound healing. 13,14 TNC is known to play a crucial role in the development of various fibrosis conditions. 15,16 In our study, we observed a significant elevation in TNC expression in hypertrophic scars compared to normal skin tissue. Knocking down TNC effectively inhibited collagen production and ECM deposition in human skin fibroblasts, improving tissue structure and inhibiting hypertrophic scar formation. This effect may be achieved through involvement of the TGF-β signaling pathway, and PI3K-Akt signaling pathway, shedding light on potential mechanisms underlying HS formation and providing a novel strategy for clinical treatment of HS. 4,17 Our research complies with the Declaration of Helsinki. 27 samples of hypert -Abstract Truncated-

The Role of Tenascin-C in Hypertrophic Scar Formation: Insights from Cell and Animal Experiments

Co-transfection of Hepatocyte Growth Factor and Truncated TGF-β Type II Receptor Inhibit Scar Formation

[The Expression of Tenascin-C Mrna in Keloids and Hypertrophic Scars].

[Study on the Expression of Tenascin-C in Keloid and Hyperplastic Scar].

HOXC10 promotes hypertrophic scar fibroblast fibrosis through the regulation of STMN2 and the TGF-β/Smad signaling pathway

Effects Of Integrin Alpha(V)Beta(3) On Differentiation And Collagen Synthesis Induced By Connective Tissue Growth Factor In Human Hypertrophic Scar Fibroblasts

The role of ERK and JNK signaling in connective tissue growth factor induced extracellular matrix protein production and scar formation

Inhibition of Notch Intracellular Domain Suppresses Cell Activation and Fibrotic Factors Production in Hypertrophic Scar Fibroblasts Versus Normal Skin Fibroblasts.

MicroRNA‑185 regulates transforming growth factor‑β1 and collagen‑1 in hypertrophic scar fibroblasts.

PTEN hinders the formation of scars by regulating the levels of proteins in the extracellular matrix and promoting the apoptosis of dermal fibroblasts through Bcl-xL

Angiogenesis modulation-mediated inhibitory effects of tacrolimus on hypertrophic scar formation

SnoN residue (1–366) attenuates hypertrophic scars through resistance to transforming growth factor-β1-induced degradation

Inhibition of FKBP10 Attenuates Hypertrophic Scarring Through Suppressing Fibroblast Activity and Extracellular Matrix Deposition.

Inhibitory effect of TGF-β peptide antagonist on the fibrotic phenotype of human hypertrophic scar fibroblasts

miR-211-5p inhibits the proliferation, migration, invasion, and induces apoptosis of human hypertrophic scar fibroblasts by regulating TGFβR2 expression

Decorin attenuates hypertrophic scar fibrosis via TGFβ/Smad signalling

MicroRNA-143-3p inhibits hyperplastic scar formation by targeting connective tissue growth factor CTGF/CCN2 via the Akt/mTOR pathway

Knockdown of ZEB1 Inhibits Hypertrophic Scarring Through Suppressing the Wnt/β-Catenin Signaling Pathway in a Mouse Model.

Cryptotanshinone Downregulates the Profibrotic Activities of Hypertrophic Scar Fibroblasts and Accelerates Wound Healing: A Potential Therapy for the Reduction of Skin Scarring

Downregulation of CFTR Is Involved in the Formation of Hypertrophic Scars

Curcumin alleviates hypertrophic scarring by inhibiting fibroblast activation and regulating tissue inflammation